Evidence map›Paper›PMID 41631502›Full record

ArticleInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2026

Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancer.

Andrew S Mikhail, Sandeep Gurram, Vladimir A Valera, Dieter Haemmerich, Nikhil Gopal, Ivane Bakhutashvili, William Richardson, Cody J Peer, Matthew F Starost, Charles Hesswani and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Andrew S MikhailCenter for Interventional Oncology, Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-9206-5765
Sandeep GurramUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Vladimir A ValeraUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Dieter HaemmerichDepartment of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.
Nikhil GopalUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Ivane BakhutashviliCenter for Interventional Oncology, Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
William RichardsonClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Cody J PeerClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Matthew F StarostDivision of Veterinary Resources, National Institutes of Health, Bethesda, Maryland, USA.
Charles HesswaniUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Keith T SchmidtClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0009-0008-0285-0216
William D FiggClinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-2428-5613
John W KaranianCenter for Interventional Oncology, Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
William F PritchardCenter for Interventional Oncology, Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-5805-5344
Bradford J WoodCenter for Interventional Oncology, Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.

Funding

Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Pharmacokinetic and Pharmacodynamic Modeling of Anticancer AgentsZ01BC010548 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2003 to 2008
$815k
Sample Processing and Analytical Methods Development for New Anticancer AgentsZ01SC006536 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 1997 to 2008
$731k
Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZ01SC006537 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 1997 to 2008
$379k
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
Intramural NIH HHS Z01 BC010548Intramural NIH HHS Z01 SC006536Intramural NIH HHS Z01 SC006537Intramural NIH HHS ZIA CL040015Intramural NIH HHS ZID BC011242NIH HHS Z01 1ZID BC011242
6 · The paper itself

Abstract

purposeTo evaluate the safety and pharmacokinetics of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox MATERIALS AND

methodsFour healthy swine received a 30-minute intravenous infusion of LTLD in combination with HIVEC, consisting of one hour of warm MMC bladder recirculation. Full-thickness bladder wall specimens were surgically resected within 30 min of HIVEC completion for histologic analysis and assessment of doxorubicin (DOX) intrinsic fluorescence in cross sections. DOX and MMC concentrations were also measured in bladder specimens and in serial blood samples up to 4 h by LC/MS. Swine were monitored for 28 days for signs of toxicity and were weighed weekly. Complete blood counts were performed at 4 h and 28 days. Cystoscopy was performed at 28 days, and bladder tissue was collected for histology and quantification of drug concentrations.

resultsMean DOX concentration in the bladder wall 30 min after treatment was 13.6 ± 4.67 µg/g, and DOX fluorescence was visible in all layers. Plasma DOX C

conclusionsIntravenous LTLD combined with MMC HIVEC was feasible and well tolerated in swine.

Indexed as

Antibiotics, AntineoplasticDoxorubicinHyperthermia, InducedMitomycinUrinary Bladder NeoplasmsAdministration, IntravesicalAnimalsFemaleNon-Muscle Invasive Bladder NeoplasmsPolyethylene GlycolsSwineAntibiotics, AntineoplasticDoxorubicinliposomal doxorubicinMitomycinPolyethylene GlycolsdoxorubicinhyperthermialiposomesmitomycinUrinary bladder neoplasms

Identifiers

PMID41631502
PMCPMC13532398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.